Acyclovir
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antivirals | Acyclovir | 2.5-5mg/kg IV/PO Q24H | Administer Post-HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 225 | 40-70 | 2.1-3.8 | 20 | 15-30 | 0.7 | 81.8-113 | 40-60 (N/A) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00787
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Krasny H, Liao S, de Miranda P, Laskin O, Whelton A, Lietman P. Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. The American journal of medicine 1982; 73(1A), 202-4.
- Laskin O, Longstreth J, Whelton A et al. Effect of renal failure on the pharmacokinetics of acyclovir. The American journal of medicine 1982; 73(1A), 197-201.
- Laskin O, Longstreth J, Whelton A et al. Acyclovir kinetics in end-stage renal disease. Clinical pharmacology and therapeutics 1982; 31(5), 594-601.
- Matzke G. Status of Hemodialysis of Drugs in 2002. Journal of Pharmacy Practice 2002; 15(5), 405-418.